The Business Brew23 Jul 2024

Unlocking REIT Potential with Bill Chen: Navigating Multifamily and Office Market Dynamics

Bill Chen returns to The Business Brew to explore the current landscape of Real Estate Investment Trusts (REITs). Delve into Chen's comprehensive due diligence process, investment strategies, and the future of multifamily and office REITs. Discover key insights on market conditions, cap rates, capital allocation, and the impact of interest rates on investment returns.

The discussion also highlights strategic decisions by large-cap public REITs, dealing with distressed assets, and the potential risks and opportunities in today's real estate market.

A must-watch for anyone looking to understand the intricacies of real estate investing in uncertain times.

Note: This episode was recorded on July 9, 2024.

00:00 - Welcome to The Business Brew

00:05 - Introducing Bill Chen and REITs Discussion

00:35 - A Walk-Through Manhattan with Bill Chen

03:28 - The Future of Office Spaces

09:48 - Bank Balance Sheets and Office Exposure

19:24 - Analyzing REIT Investments

38:12 - Analyzing Cap Rates in Real Estate Investments

41:45 - The Impact of Public Company Costs on Returns

49:30 - Liquidity and Market Dynamics in Real Estate

53:11 - Challenges and Opportunities in the Current Market

1:00:10 - Grocery-Anchored Shopping Centers: A Resilient Asset Class

1:06:17 - Interest Rates and Their Influence on Real Estate Returns

1:15:02 - Understanding Real Estate Multiples and Leverage

1:15:41 - Market Fears and Multifamily Capitalization Rates

1:16:32 - Challenges in Real Estate Development

1:16:56 - Opportunities in a Down Market

1:17:20 - Connecting with the Speaker

1:18:25 - Investment Strategies and Market Timing

1:19:51 - Balancing Market Humility and Aggression

1:21:23 - Psychological Approaches to Real Estate Investment

1:23:24 - Resilience of Multifamily Assets

1:24:48 - The Future of Home Ownership and Renting

1:27:54 - Personal Experiences with Real Estate

1:30:56 - The REIT Mafia and Investment Benchmarks

1:35:16 - Long-Term Investment Perspectives

1:42:22 - Final Thoughts and Farewell

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(202)

Steve Hou - Data Over Narrative

Steve Hou, Head of Research at Silicon Data, stops by to discuss solving problems associated with AI capex financing. Silicon Data provides users with a number of indices and data sets tracking everyt...

23 Sep 1h 16min

Another Cyclical Masterclass with Robotti & Company

Bob Robotti stops by for a follow up episode. David Kessler, Portfolio Manager and Securities Analyst at Robotti & Company, is in the room with Bob to provide some additional analytical firepower. Thi...

27 Aug 1h 38min

Another FDA vs uniQure Episode

Peter Mantas returns to the show. This is a follow up episode to the episode discussing uniQure. It's timely given the amount of media attention Marty Makary is getting; in part because of uniQure. De...

7 Mai 1h 20min

Revisiting Fairfax Financial

Charles Frischer and Asheef Lalani stop by The Business Brew to update the listeners on Fairfax Financial. They originally came on the program on 7/20/2023 when the stock was quite unloved. Bill asked...

30 Apr 1h 31min

Evan Tindell

Evan Tindell, CIO at Bireme Capital, returns to The Brew for a laid back conversation. The impetus for the conversation is Evan's Q4 letter. A year ago Evan came on the show to educate people about ...

24 Apr 1h 37min

Sonu Chawla - Managing Mid Cap Exposure - $TSCM

Sonu Chawla of Times Square Capital Management shares her investment philosophy, focusing on growth with a conscience, valuation discipline, and management assessment. Stocks discussed include Argenx,...

26 Mar 1h 12min

Notes From The Beauty Contest

@crashkolnikov on X, and author of Notes From The Beauty Contest Substack, joins the show. Notes From The Beauty Contest is a long form Substack that focuses on stocks that are somewhat under covered ...

21 Mar 1h 51min

Current Events - uniQure and the FDA

uniQure is a business that develops gene therapies. uniQure's AMT-130 is currently in the headlines. This podcast episode attempts to present the Huntington's Disease community's arguments for why the...

6 Mar 1h 35min